Risk for low visual acuity after 1 and 2 years of treatment with ranibizumab or bevacizumab for patients with neovascular age-related macular degeneration
Conclusion:Treatment with anti-vascular endothelial growth factor intravitreal injections mainly maintains the visual acuity level, and only approximately 20% and 40% of the patients required vision rehabilitation after 1 year and 2 years, respectively.
Source: RETINA - Category: Opthalmology Tags: Original Study Source Type: research
More News: Age-Related Macular Degeneration (AMD) | Avastin | Diabetes | Endocrinology | Lucentis | Ranibizumab Injection | Rehabilitation | Study | Sweden Health